Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad Announces Third Quarter 2017 Business Update

Celyad Announces Third Quarter 2017 Business Update

Conference call - Update on Clinical Strategy

Conference call - Update on Clinical Strategy

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Discover our news

Upcoming events

Nov 29-30, 2017

Digital Health World Congress

Dec 6-7, 2017

Cell therapy & Gene therapy

Discover all events

Press material

Dear Journalists,
Please find here all information background and material for your articles.
For any media request, please refer to the contacts below.
Join our press list
Press kit

Press kit

2.8 Mo

a

Press contacts

Celyad

Nicolas Van Hoecke
Director, Investor Relations & Communications

+32 (0)10 39 41 84

Stern Investor Relations (US)

Will O’Connor, Michael Schaffzin

+1 212 362 1200

Consilium Strategic Communications (UK)

Chris Welsh, Chris Gardner

+44 20 3709 5700

NewCap (France)

Nicolas Merigeau, Pierre Laurent

+ 33(0)1 44 71 94 94

Comfi (Belgium)

Gunther De Backer, Sabine Leclercq

+32(0) 2 290 90 91